Samsung Biologics Highlights ADC Manufacturing Strength
Operates Full ADC Process at Single Songdo Site, Launched Dedicated Facility in March 2025 and Plans DP Line by 2027 Samsung Biologics participated in "World ADC San Diego 2026," held for four days from October 12 to 15 in San Diego, California. Marking its third consecutive year operating a standal
Samsung Biologics has emphasized its manufacturing capabilities in the field of ADCs (Antibody Drug Conjugates) at the World ADC San Diego 2026 event, taking place from October 12 to 15 in San Diego, California. The company has been operating a full ADC process at a single site in Songdo, Incheon since launching its dedicated ADC production facility in March 2025.
Samsung Biologics aims to further bolster its end-to-end service system by establishing and commencing operations of a dedicated ADC drug product (DP) line by 2027. The company highlighted its strengths in Contract Research Organization (CRO), Contract Development Organization (CDO), and Contract Manufacturing Organization (CMO) services, showcasing its ability to handle the entire ADC manufacturing process.
Additionally, Samsung Biologics is planning to expand its biopharmaceutical conjugation services and is set to introduce new modalities such as peptides to further solidify its response capabilities to diverse customer needs.
Brief written by urgent.news from BusinessKorea's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
